Short versus long infusion of meropenem in very-low-birth-weight neonates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4760-4764

  Padari, Helgi ^a   Metsvaht, Tuuli ^a   Kõrgvee, Lenne Triin ^a   Germovsek, Eva ^b   Ilmoja, Mari Liis ^c   Kipper, Karin ^d   Herodes, Koit ^d   Standing, Joseph F ^b   Oselin, Kersti ^a   Lutsare, Irja ^e  

^a TARTU UNIVERSITY HOSPITAL   (Estonia)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c TALLINN CHILDREN S HOSPITAL   (Estonia)

^d UNIVERSITY OF TARTU   (Estonia)

^e UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; MEROPENEM;

ARTICLE; BACTEREMIA; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VERY LOW BIRTH WEIGHT;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ENTEROCOLITIS, NECROTIZING; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; INFUSIONS, INTRAVENOUS; MALE; MODELS, STATISTICAL; PNEUMONIA; SEPSIS; SOFTWARE; THIENAMYCINS;

EID: 84865440785     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00655-12     Document Type: Article

References (37)

1. Abramowicz M, Klein JO, Ingall D, Finland M. 1966. Levels of penicillin in serum of newborn infants. Am. J. Dis. Child. 111:267-271.
2. AstraZeneca. 2011. Meropenem: summary of product characteristics. State Agency of Medicines, Tallinn, Estonia.
3. Beal S, Sheiner L, Boeckmann A, Bauer R. 2009. NONMEM user's guides (1989-2009). Icon Development Solutions, Ellicott City, MD.
4. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. 2010. Stability of meropenem and doripenem solutions for administration by continuous infusion. J. Antimicrob. Chemother. 65:1073-1075.
5. Blumer JL. 1996. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr. Infect. Dis. J. 15:733-737. (Pubitemid 26271994)
6. Bradley JS, et al. 2008. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr. Infect. Dis. J. 27:794-799.
7. Bromiker R, Arad I, Peleg O, Preminger A, Engelhard D. 2001. Neonatal bacteremia: patterns of antibiotic resistance. Infect. Control Hosp. Epidemiol. 22:767-770. (Pubitemid 34157718)
8. Ceriotti F, et al. 2008. Reference intervals for serum creatinine concentrations: assessment of available data for global application. Clin. Chem. 54:559-566. (Pubitemid 351359026)
9. Condon RE, et al. 1997. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin. Infect. Dis. 24(Suppl. 2):S181-S183. (Pubitemid 27130705)
10. De Cunto A, et al. 2007. Use of meropenem in preterm newborns. Survey of the literature and case series. Minerva Pediatr. 59:755-760. (Pubitemid 350247596)
11. Drusano GL, Hutchison M. 1995. The pharmacokinetics of meropenem. Scand. J. Infect. Dis. Suppl. 96:11-16.
12. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob. Agents Chemother. 53:2266-2273.
13. EUCAST. 2010. Antimicrobial wild type distributions of microorganisms. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden.
14. Gray JW, Patel M. 2011. Management of antibiotic-resistant infection in the newborn. Arch. Dis. Child. Educ. Pract. Ed. 96:122-127.
15. Hurst M, Lamb HM. 2000. Meropenem: a review of its use in patients in intensive care. Drugs 59:653-680. (Pubitemid 30213867)
16. Jaruratanasirikul S, et al. 2011. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int. J. Antimicrob. Agents 38:231-236.
17. Kipper K, et al. 2009. Rapid determination of meropenem in biological fluids by LC: comparison of various methods for sample preparation and investigation of meropenem stability. Chromatographia 70:1423-1427.
18. Köksal N, Hacimustafaoglu M, Bagci S, Celebi S. 2001. Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. Indian J. Pediatr. 68:15-19. (Pubitemid 32199858)
19. Lingvall M, Reith D, Broadbent R. 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br. J. Clin. Pharmacol. 59:54-61. (Pubitemid 40040096)
20. Lutsar I, et al. 2011. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials 12:215. doi:10.1186/1745-6215-12-215.
21. Manduru M, et al. 1997. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 41:2053-2056. (Pubitemid 27383259)
22. Muller-Pebody B, et al. 2011. Empirical treatment of neonatal sepsis: are the current guidelines adequate? Arch. Dis. Child. Fetal Neonatal Ed. 96:F4-F8.
23. Ohata Y, et al. 2011. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. Drug Metab. Pharmacokinet. 26:523-531.
24. Patel PR, Cook SE. 1997. Stability of meropenem in intravenous solutions. Am. J. Health Syst. Pharm. 54:412-421. (Pubitemid 27089727)
25. Rhodin MM, et al. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24:67-76.
26. Ribbing J, Jonsson EN. 2004. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J. Pharmacokinet. Pharmacodyn. 31:109-134. (Pubitemid 38932393)
27. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott NJ. 2009. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J. Pharm. Pharmacol. 61:465-471.
28. Smith PB, et al. 2011. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr. Infect. Dis. J. 30:844-849.
29. Smith PB, et al. 2009. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect. Dis. J. 28:412-415.
30. Standing J, Morris J, Germovsek E, Lutsar I, Cortina-Borja M. 2011. Methods for optimising neonatal antimicrobial use: time-and concentration- dependent agents, poster IV-12. 20th Annual Meeting of the Population Approach Group in Europe, Athens, Greece.
31. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. 50:425-428.
32. Tam VH, et al. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927. (Pubitemid 41778901)
33. Thalhammer F, et al. 1999. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 43:523-527. (Pubitemid 29182302)
34. Tod M, Jullien V, Pons G. 2008. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47:231-243. (Pubitemid 351367434)
35. van den Anker JN, et al. 2009. Meropenem pharmacokinetics in the newborn. Antimicrob. Agents Chemother. 53:3871-3879.
36. van Enk JG, Touw DJ, Lafeber HN. 2001. Pharmacokinetics of meropenem in preterm neonates. Ther. Drug Monit. 23:198-201. (Pubitemid 32476544)
37. Yatsyk GV. 1998. Use of meropenem in the treatment of severe infections in newborns. Antibiot. Khimioter. 43:32-33. (In Russian.)